R.I.P. and Thanks Johns Hopkins Coronavirus Resource Center


As of last Friday, Johns Hopkins University pulled the plug on its popular Coronavirus Resource Center. The site ran for just over three years, and was an interdisciplinary collaboration between JHU's Applied Physics Laboratory, the Bloomberg School of Public Health, the Center for Systems Science and Engineering in the Whiting School of Engineering, the School of Medicine, Sheridan Libraries, and the Bloomberg Center for Government Excellence.

The World Economic Forum called the site "One of the most vital and trusted resources in the fight against the spread of COVID-19." Astonishingly, it was viewed more than 2.5 billion times. This blog accounted for a few of those visits, and you'll find it linked several times in previous posts. It was an important resource for my reporting.

They are closing the site because vaccines have reduced the risk of death, and because reliable public health data was becoming increasingly hard to get at the global scale the dashboard covered. The site and its data will remain available, but it will no longer be updated.

Thanks to the JHU people for making it happen!

Popular posts from this blog

Looks Like Immune Responses are Enduring After All

Image
 For some time, public health officials have fretted about whether immunity to COVID-19, acquired via infection or vaccination would stick.  Studies showed rapid declines in antibodies during recovery from infection and thereafter . It turns out that this concern was overblown. A study just released says bone marrow plasma cells are a persistent source of protective antibodies, and that "circulating resting memory B cells directed against the S protein were detected in the convalescent individuals."   Another study , yet to be reviewed, suggests that vaccines boost this effect. In fact, some are suggesting this situation this could actually mean  lifetime immunity .   Whether the same thing happens with vaccination is not clear. Most estimates suggest that vaccine immunity will last about a year . More pessimistic estimates putting the protection period at six months .  The possible shorter time frame, plus the appearance of the new variants, have the vaccine makers working
Read more

Another One Bites the Dust

Image
Hi all. Stepping out of retirement for a moment to say that the day has finally arrived. After four years of successfully avoiding COVID-19 infection I had a positive test yesterday. Symptoms are very mild—I've had worse colds. The provider at urgent care said almost all the cases they are seeing are the same. Mild symptoms may also be due to the fact that I had the original vaccine then the two boosters. All this time I thought I might be a NOVID —one of those people who never get the bug. But no, it must have been my assiduous mask wearing and avoidance of high-risk situations when things were bad. So here's double middle fingers to all the kooks who think masks don't work (I've not been wearing masks for months now). I don't know what variant I have but it's likely JN.1. It is said to be extraordinarily contagious and accounts for 60% of cases worldwide . It also tends to produce mild infections like the one I have.  This article claims that right now every
Read more

AZ Pandemic Numbers Summary for the Seven Days Ending November 9: Everything is Going South

Image
Here are the Arizona pandemic numbers and graph of statewide cases for the seven day period ending yesterday: Well this isn't good. The lull seems to be over. Virtually every number is up, both over a week and over four weeks. The most worrisome is hospital beds, which have been steadily trending up over the last several weeks.  Wastewater signals are all up except Tempe (dashboard is up again) which after going up last week (from 41 to 100) decreased by about 10%. The increases are worrisome because the latest data from ASU's Lim Lab (last updated October 31), where they sequence PCR samples to identify variants, shows that only about 46% of sequences showed BA.5. That is one of the Omicron variants the new bivalent vaccine was designed to protect against.  All the rest of the samples are BA.2.75 (7.7%), which I flagged several weeks ago, and BQ,1.1 (15.4%), and BQ.1 (30.8%), both of which I blogged about a couple weeks ago.  Those, new research confirms , are much more lik
Read more